TransMedics Group, Inc. (TMDX) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 11 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026after close 36 8-K
Q2 FY2026Tue, Aug 4, 2026after close 35 8-K
Q1 FY2026Tue, May 5, 2026after close 35 8-K
Q4 FY2025Tue, Feb 24, 2026after close 55 8-K
Q3 FY2025Wed, Oct 29, 2025after close 29 8-K
Q2 FY2025Wed, Jul 30, 2025after close 30 8-K
Q1 FY2025Thu, May 8, 2025after close 38 8-K
Q4 FY2024Thu, Feb 27, 2025after close 58 8-K

What they guided beta

Q3 FY2026 "PRESS RELEASE TransMedics Reports Third Quarter 2026 Financial Results Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and Mid-Term Catalysts Andover, Mass. – November 5, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2026." exhibit
Q3 FY2026 "Raises full-year 2026 revenue guidance to between $764-$774 million, inclusive of approximately $14 million from PAD Aviation Recent Business Highlights" exhibit
Read from the sentence: revenue $764 million to $774 million, FY2026
Q3 FY2026 "Cash was $493.0 million as of September 30, 2026. 2026 Financial Outlook TransMedics raises its full-year 2026 revenue guidance." exhibit
Q3 FY2026 "Prior Guidance Updated Guidance Implied Annual Growth (compared to FY 2025 revenue)" exhibit
Q3 FY2026 "A live and archived webcast of the event and the company’s slide presentation with information on third quarter 2026 financial results will be available on the “Investors” section of the TransMedics website at www.transmedics.com ." exhibit
Q2 FY2026 "Raised low end of full-year 2026 revenue guidance, excluding PAD Aviation, to a range of $737 million to $757 million" exhibit
Q2 FY2026 "Cash was $472.7 million as of June 30, 2026. 2026 Financial Outlook TransMedics is raising the low end of its full-year 2026 revenue guidance to a range of $737 million to $757 million." exhibit
Q2 FY2026 "TransMedics’ full year 2026 revenue guidance as reported on May 5, 2026 was previously in the range of $727 million to $757 million." exhibit
Q2 FY2026 "A live and archived webcast of the event and the company’s slide presentation with information on second quarter 2026 financial results will be available on the “Investors” section of the TransMedics website at www.transmedics.com ." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/TMDX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/TMDX

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

TMDX earnings date badge

HTML

<a href="https://veritasdata.dev/company/TMDX/"><img src="https://veritasdata.dev/embed/TMDX.svg" alt="TMDX earnings date" width="240" height="56"></a>

Markdown

[![TMDX earnings date](https://veritasdata.dev/embed/TMDX.svg)](https://veritasdata.dev/company/TMDX/)

Script

<script async src="https://veritasdata.dev/embed/TMDX.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/TMDX"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.